![Jason Keyes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jason Keyes
Directeur/Membre du Conseil chez
ACTUATE THERAPEUTICS, INC.
Fortune : 367 236 $ au 31/05/2026
Profil
Jason A. Keyes is currently an Independent Director at Actuate Therapeutics, Inc. since 2024.
Formerly, Mr. Keyes was Senior Director-Finance at Amylin Pharmaceuticals, Inc. from 2007 to 2013.
Served as Independent Director at Sesen Bio, Inc. from 2020 to 2023.
Held the position of Chief Financial Officer & Executive Vice President at Orexigen Therapeutics, Inc. from 2016 to 2018.
Worked at Amgen, Inc. as Head-Finance & Strategy.
Was Chief Financial Officer at Equillium, Inc. from 2018 to 2025.
Education includes undergraduate and graduate degrees from Stanford University and an MBA from UCLA Anderson School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EQUILLIUM, INC. 0,2 % | 14/02/2025 | 126 633 ( 0,2 % ) | 367 236 $ | 31/05/2026 |
| 21/05/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Jason Keyes
| Sociétés | Poste | Début |
|---|---|---|
| ACTUATE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 12/08/2024 |
Anciens postes connus de Jason Keyes
| Sociétés | Poste | Fin |
|---|---|---|
| EQUILLIUM, INC. | Directeur Financier/CFO | 25/04/2025 |
| CARISMA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 07/03/2023 |
| OREXIGEN THERAPEUTICS, INC. | Directeur Financier/CFO | 23/02/2018 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Directeur Financier/CFO | 01/01/2013 |
| AMGEN INC. | Corporate Officer/Principal | - |
Formation de Jason Keyes
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
56
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on the treatment of obesity | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics to treat eye diseases | Health Technology |
UCLA Anderson School of Management
 UCLA Anderson School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Actuate Therapeutics, Inc.
 Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops novel therapeutics which target cancers and neurodegenerative diseases | Health Technology |
Equillium, Inc.
 Equillium, Inc. BiotechnologyHealth Technology Engages in the development of products for severe immune-inflammatory disorders | Health Technology |
